Healthcare

Pemetrexed Market Intelligence Report Offers Growth Prospects

Pemetrexed Market
Pemetrexed Market

“Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industry analysis helps an organization formulate strategies and policies of a business.”

Coherent Market Insights released a new market study on 2018-2026 Pemetrexed Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The global research report delivers an in-depth watch on leading competitors with strategic analysis, small and macro business trends and eventualities, valuation analysis and a holistic summary within the forecast amount. Its knowledge and in-depth reports specializing in primary and secondary drivers, market share, leading segments, and geographical analysis. Further, key players, major collaborations, merger & acquisitions of trending innovation and business policies reviewed within the report. The report contains basic, secondary and advanced data referring to international standing and trend, size, share, growth, trends analysis, section, and forecasts.

Have a look on Sample Version of Report: https://www.coherentmarketinsights.com/insight/request-sample/2458

Detailing the crucial pointers outlined in the Pemetrexed Market research report:

Summary:

Pemetrexed is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed is a patented drug of Eli Lilly and Company and sold under brand name Alimta. In 2004, Alimta (Pemetrexed injection) was approved by FDA in combination with cisplatin as an initial treatment for patients with malignant pleural mesothelioma. In 2008, ALIMTA, in combination with cisplatin, was approved as an initial chemotherapy treatment for locally advanced or metastatic NSCLC for patients with nonsquamous histology, and in 2009, ALIMTA was approved as a maintenance therapy for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).

Market Dynamics

Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to support global pemetrexed market growth over the forecast period.

For instance, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.

High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for Pemetrexed for its treatment and support global pemetrexed market growth over the forecast period.

For instance, according to the data published by American Society of Clinical Oncology, in January 2018, in the U.S. around 234,030 adults (121,680 men and 112,350 women) were diagnosed with lung cancer among which non-small cell lung cancer is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer diagnose.

Furthermore, key players in the market are dedicated to expand the indication of its Pemetrexed drugs in order to increase its sale and generate high revenues. For instance, in June 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for a new indication for ALIMTA (pemetrexed for injection) in combination with carboplatin and KEYTRUDA (pembrolizumab) for the initial treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status.

A synopsis of the regional landscape of the market:

  • The research report broadly enumerates the regional terrain of this industry. As per the study, regional landscape is bifurcated into:
    • North America: United States, Canada, and Mexico.
    • South & Central America: Argentina, Chile, and Brazil.
    • Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt, and South Africa.
    • Europe: UK, France, Italy, Germany, Spain, and Russia.
    • Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.
  • The study delivers substantial information pertaining to the market share that every region is estimated to hold, in tandem with the growth opportunities projected for each geography.
  • The report depicts the growth rate in which every topography is estimated to register over the forecast time period.

An outline of the competitive landscape of the market:

  • The comprehensive market report is inclusive of a detailed summary of the competitive analysis of this industry. As per the document, companies along the likes of Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc., and others. are encompassed in the competitive spectrum of the market.
  • Data related production sites, market share, area served, and more have been covered in the report.
  • The report elucidates data pertaining to the manufacturer’s product portfolio, product specifications, as well as numerous product applications.
  • A brief outline of the firm in question, its profit margins and pricing models are explained in the report as well.

Some Points from Table of Content:

1. Overview and Scope

1.1. Research goal & scope

1.2. Research assumptions

1.3. Research methodology

1.3.1. Primary data sources

1.3.2. Secondary data sources

1.4. Key takeaway

1.5. Stakeholders

2. Executive Summary

2.1. Market definition

2.2. Market segmentation

3. Pemetrexed Market Insights

3.1. Pemetrexed – Industry snapshot

3.1.1. Leading Companies

3.1.2. Key Companies to Watch

3.2. Pemetrexed – Ecosystem analysis

3.2.1. Market overview

3.2.2. Commercial Landscape

3.3. Pemetrexed Market Dynamics

3.3.1. – Market Forces

3.3.1.1. Market Driver Analysis

3.3.1.2. Market Restraint/Challenges analysis

3.3.1.3. Market Opportunity Analysis

3.4. Industry analysis – Porter’s five forces

3.4.1. Bargaining power of supplier

3.4.2. Bargaining power of the buyer

3.4.3. Threat of substitute

3.4.4. The threat of new entrant

3.4.5. Degree of competition

3.5. Market PEST Analysis

3.6. Market Value Chain Analysis

3.7. Industry Trends

3.8. Competitive Ranking Analysis

Continued…………..

Speak to one of our analysts please click @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2458

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.